Back to Search
Start Over
The neutrophil-lymphocyte ratio has a role in predicting the effectiveness of nivolumab in Japanese patients with metastatic renal cell carcinoma: a multi-institutional retrospective study.
- Source :
-
BMC urology [BMC Urol] 2020 Jul 25; Vol. 20 (1), pp. 110. Date of Electronic Publication: 2020 Jul 25. - Publication Year :
- 2020
-
Abstract
- Background: The neutrophil-lymphocyte ratio (NLR) is a well-known prognostic marker in various cancers. However, its role as a predictive marker for the effectiveness of nivolumab in patients with metastatic RCC (mRCC) remains unclear. We evaluated the relationships between the NLR and progression-free survival (PFS) or overall survival (OS) in mRCC patients treated with nivolumab.<br />Methods: The data of 52 mRCC patients who received nivolumab therapy were collected from seven institutes and evaluated. The median follow-up period from treatment with nivolumab was 25.2 months (IQR 15.5-33.2).<br />Results: The median duration of nivolumab therapy was 7.1 months (IQR 2.9-24.4). The objective response rate was 25% and the 1- and 2-year PFS rates were 46.2 and 25.2%, respectively. The median NLR values at baseline and 4 weeks were 3.7 (IQR 2.7-5.1) and 3.3 (IQR 2.4-5.7), respectively. In the multivariate analysis, an NLR of ≥3 at 4 weeks was an independent predictor of PFS (P = 0.013) and OS (P = 0.034). The 1-year PFS of patients with an NLR of < 3 at 4 weeks was better than that of those with an NLR of ≥3 (75% versus 29%, P = 0.011). The 1-year OS of patients with an NLR of < 3 at 4 weeks was also better than that of those with an NLR of ≥3 (95% versus 71%, P = 0.020).<br />Conclusions: Although the baseline NLR was not associated with PFS or OS, an NLR of ≥3 at 4 weeks after the initiation of therapy might be a robust predictor of poor PFS and OS in mRCC patients undergoing sequential treatment with nivolumab.
- Subjects :
- Adult
Aged
Aged, 80 and over
Carcinoma, Renal Cell secondary
Female
Humans
Japan
Kidney Neoplasms pathology
Male
Middle Aged
Retrospective Studies
Antineoplastic Agents, Immunological therapeutic use
Carcinoma, Renal Cell blood
Carcinoma, Renal Cell drug therapy
Kidney Neoplasms blood
Kidney Neoplasms drug therapy
Lymphocytes
Neutrophils
Nivolumab therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1471-2490
- Volume :
- 20
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- BMC urology
- Publication Type :
- Academic Journal
- Accession number :
- 32711491
- Full Text :
- https://doi.org/10.1186/s12894-020-00679-2